# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-186928
Filing Date
2026-04-28
Accepted
2026-04-28 16:05:21
Documents
16
Period of Report
2026-04-21

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | alec-20260421.htm iXBRL | DEF 14A | 1903027
2 | GRAPHIC | img213373948_0.jpg | GRAPHIC | 110934
3 | GRAPHIC | img213373948_1.gif | GRAPHIC | 159811
4 | GRAPHIC | img213373948_2.jpg | GRAPHIC | 3720364
5 | GRAPHIC | img213373948_3.jpg | GRAPHIC | 1714193
| Complete submission text file | 0001193125-26-186928.txt |  | 16768251

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | alec-20260421.xsd | EX-101.SCH | 27225
19 | EXTRACTED XBRL INSTANCE DOCUMENT | alec-20260421_htm.xml | XML | 309954

Mailing Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080 415-231-5660
Alector, Inc. (Filer) CIK: 0001653087 (see all company filings)

EIN.: 822933343 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38792 | Film No.: 26907577
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)